HER2-low
1 drugsPredictive biomarker for patient selection in 5 indications
1
Approved Drugs
5
Indications
1
Companies
HER2-low is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 5 indications including Unresectable or metastatic HER2-positive breast cancer, Unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer, Unresectable or metastatic HER2-low breast cancer. Explore the targeted therapies, indications, testing methods, and companies developing HER2-low drugs below.
Search HER2-low Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting HER2-low
| Drug | Company | Therapeutic Area |
|---|---|---|
| ENHERTU | DAIICHI SANKYO INC | Oncology |
HER2-low Indications
Unresectable or metastatic HER2-positive breast cancer Unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer Unresectable or metastatic HER2-low breast cancer Unresectable or metastatic HER2-mutant non-small cell lung cancer Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma